Pancreatic Cancer Research

ResearcherFox Chase Cancer CenterActive in the last 2 years

Igor A. Astsaturov

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8613-1890; OpenAlex author ID A5087332592. Sources: OpenAlex.

Their work

Papers
19 (first author 1, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
78
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: none · 2014: none · 2015: none · 2016: 2 papers · 2017: 2 papers · 2018: none · 2019: none · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: 3 papers · 2024: 1 paper · 2025: 1 paper · 2026: 4 papers

Papers 19

  1. Oncogenic KRAS-driven type I interferon signalling primes pancreatic cancer for necroptosis. Co-author DOI 10.1038/s41467-026-73189-8↗
  2. Optimization of first-line treatment selection in advanced pancreatic adenocarcinoma using artificial intelligence. Co-author DOI 10.1038/s41698-026-01543-6↗
  3. ANO6-mediated trogocytosis of cancer-associated fibroblasts promotes pancreatic cancer cell growth and immune suppression. Last author DOI 10.1038/s43018-026-01265-5↗
  4. Autophagy inhibition in pancreatic cancer: hope or hype? Co-author DOI 10.1080/27694127.2026.2721748↗
  5. Racial/Ethnic Differences and Effects of Clinical/Socioeconomic Factors on Time from Diagnosis to Treatment in Pancreatic Cancer. Co-author DOI 10.1007/s12029-025-01188-x↗
  6. Protocol for isolating extracellular vesicles from pancreatic cancer cells for liver metastatic niche research. Co-author DOI 10.1016/j.xpro.2024.103256↗
  7. Intrapancreatic fat, pancreatitis, and pancreatic cancer. First author DOI 10.1007/s00018-023-04855-z↗
  8. Netrin-1 feedforward mechanism promotes pancreatic cancer liver metastasis via hepatic stellate cell activation, retinoid, and ELF3 signaling. Co-author DOI 10.1016/j.celrep.2023.113369↗
  9. Tumor-Suppressive and Immune-Stimulating Roles of Cholesterol 25-hydroxylase in Pancreatic Cancer Cells. Co-author DOI 10.1158/1541-7786.mcr-22-0602↗
  10. Identification of New Regulators of Pancreatic Cancer Cell Sensitivity to Oxaliplatin and Cisplatin. Co-author DOI 10.3390/molecules27041289↗
  11. Platelet microRNAs inhibit primary tumor growth via broad modulation of tumor cell mRNA expression in ectopic pancreatic cancer in mice. Co-author DOI 10.1371/journal.pone.0261633↗
  12. Cholesterol Pathway Inhibition Induces TGF-β Signaling to Promote Basal Differentiation in Pancreatic Cancer. Last author DOI 10.1016/j.ccell.2020.08.015↗
  13. Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-0489↗
  14. Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models. Last author DOI 10.18632/oncotarget.12642↗
  15. Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP. Co-author DOI 10.18632/oncotarget.20819↗
  16. Prognostic Significance of MUC-1 in Circulating Tumor Cells in Patients With Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000619↗
  17. Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3-MYC Interactions as a Target in Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-16-0149↗
  18. Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcin… Co-author DOI 10.1097/coc.0b013e3181d2734a↗
  19. Significance of pathologic response to preoperative therapy in pancreatic cancer. Co-author DOI 10.1245/s10434-011-2086-4↗

Closest collaborators

The 25 strongest of 78 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Edna Cukierman · 5 shared papers, 2020–2026 · strength 1.04
  2. Erica A. Golemis · 5 shared papers, 2016–2026 · strength 0.68
  3. Anna C. Lilly · 2 shared papers, 2023–2026 · strength 0.49
  4. Emma Guilbaud · 1 shared paper, 2026 · strength 0.43
  5. Lorenzo Galluzzi · 1 shared paper, 2026 · strength 0.43
  6. Charline Ogier · 3 shared papers, 2020–2026 · strength 0.40
  7. Efrat Dotan · 3 shared papers, 2016–2025 · strength 0.36
  8. Crissy Dudgeon · 2 shared papers, 2023–2024 · strength 0.33
  9. Anthony Casabianca · 2 shared papers, 2023–2024 · strength 0.33
  10. Patrick Mehlen · 2 shared papers, 2023–2024 · strength 0.33
  11. Darren R. Carpizo · 2 shared papers, 2023–2024 · strength 0.33
  12. Serge Y Fuchs · 2 shared papers, 2023–2026 · strength 0.32
  13. Debora Barbosa Vendramini Costa · 2 shared papers, 2023–2026 · strength 0.32
  14. Jason Robert Pitarresi · 2 shared papers, 2023 · strength 0.28
  15. Ralph A. Francescone III · 2 shared papers, 2020–2026 · strength 0.26
  16. Linara Gabitova-Cornell · 2 shared papers, 2020–2026 · strength 0.26
  17. Janusz Franco‐Barraza · 2 shared papers, 2020–2026 · strength 0.26
  18. Harshabad Singh · 1 shared paper, 2026 · strength 0.24
  19. P. A. Philip · 1 shared paper, 2026 · strength 0.24
  20. Sebastian Cole · 1 shared paper, 2026 · strength 0.24
  21. David B. Spetzler · 1 shared paper, 2026 · strength 0.24
  22. Peter J. Hosein · 1 shared paper, 2026 · strength 0.24
  23. Tanios Bekaii‐Saab · 1 shared paper, 2026 · strength 0.24
  24. Michael Jon Pishvaian · 1 shared paper, 2026 · strength 0.24
  25. Daniel D. Von Hoff · 1 shared paper, 2026 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.